Table 2 Patient characteristics of validation cohort
Patient | Age/Gender | Diagnosis | Indication/Type of treatment | Chemotherapy | RT dose |
|---|---|---|---|---|---|
AE1 | 58/F | IIA SCC | recurrence/adjuvant | PN | 70.0 Gy |
BE1 | 68/M | IIIA SCC | definitive | KG | 66.0 Gy |
CG1 | 55/M | IIA SCC | R2/adjuvant | PN | 68.0 Gy |
DW1 | 59/F | IIB SCC | R1/adjuvant | PN | 68.0 Gy |
FL1 | 76/M | IIIA SCC | definitive | PG | 66.0 Gy |
GH1 | 62/F | IIIB SCC | definitive | PN | 66.0 Gy |
GK1 | 67/M | IIIB SCC | definitive | KN | 66.0 Gy |
GW1 | 61/M | IIIA SCC | definitive | PG | 66.0 Gy |
KA1 | 64/F | IIIB ADENO | definitive | PN | 58.0 Gy |
KA2 | 64/M | IIB SCC | R1/adjuvant | PN | 60.0 Gy |
KI1 | 68/F | IIIA SCC | R1/adjuvant | KN | 60.0 Gy |
KM1 | 67/M | IIIA SCC | R1/adjuvant | PN | 60.0 Gy |
LJ1 | 77 M | IIIA SCC | R1/adjuvant | No chemo | 56.0 Gy |
MS1 | 70/M | IIIA SCC | R1/adjuvant | KN | 66.0 Gy |
PB1 | 60/M | IIIA NOS | definitive | PG | 64.0 Gy |
PI1 | 56/F | IIIB ADENO | definitive | PN | 66.0 Gy |
SB1 | 55/M | IIIA SCC | R1/adjuvant | PN | 69.3 Gy |
SJ1 | 55/M | IIB NOS | R1/adjuvant | PN | 66.0 Gy |
SW1 | 62/M | IIIB ADENO | definitive | PN | 66.0 Gy |
WJ1 | 73/M | IIIA ADENO | definitive | PG | 60.0 Gy |
ZA1 | 78/M | IIIA ADENO | definitive | KG | 66.0 Gy |